Carl Morris, PhD

Title: Chief Scientific Officer

Organization: Solid Biosciences

Bio: Prior to joining Solid, Dr. Morris was a Senior Director for Pfizer’s Rare Disease Research Unit, leading their efforts in neurologic diseases and the muscle biology programs. While at Pfizer, Dr. Morris directed several small molecule and biotherapeutic development programs, including a program that led to a Phase 2 study in Duchenne Muscular Dystrophy, while also heading an internal research group responsible for advancing programs from target identification to the clinic for many rare neurologic and muscle-related diseases. Dr. Morris identified key external opportunities and worked closely with patient groups, academic laboratories, and other industry partners to advance drug development in the rare neuromuscular disease space. His scientific and drug development experience at Pfizer also included investigations into broader muscle wasting conditions, as well as tendon and bone repair biology. Prior to joining Pfizer in 2007, Dr. Morris was an Assistant Professor at Boston University School of Medicine and a founding faculty member of the Muscle and Aging Research Unit, established to investigate strategies for improving muscle function during aging or disease. He completed his postdoctoral fellowship in the Department of Physiology at the University of Pennsylvania where he worked on multiple projects ranging from molecular aspects of muscle protein interactions to therapeutic approaches for modulating muscle size and function. As a trained muscle physiologist, his academic pursuits have ranged from biophysical aspects of muscle contraction and enzyme kinetics to therapeutic interventions in a variety of in vivo muscle atrophy and disease models. Dr. Morris holds a B.A. in Biology from Franklin Pierce College (Rindge, NH) and a PhD in Physiology from UCLA.

2021 FUTURES: Gene Therapy & Gene Editing Symposium

Information and updates on the gene therapy and gene editing landscape from experts in the field.

**We experienced a technical issue during this session. Please reach out with questions to Futures@CureDuchenne.org if needed.

Beth Belluscio, MD, PhD

Global Clinical Lead, Rare Neurological Disorders

Pfizer

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

Eric Olson, PhD

Chief Scientific Advisor

Vertex Pharmaceuticals

Matthew Pletcher, PhD

Division Head of Gene Therapy Research & Technical Operations

Astellas Gene Therapies

Deanna Tucker

Senior Medical Science Liaison

Sarepta Therapeutics

Genine Winslow, MSc

CEO & President

Chameleon Biosciences